Table 4.
Emergent treatment and outcomes for cohort patients (n=103).
| Item | Value | ||
| Treatments, n (%) | |||
|
|
Glucocorticoids | 50 (48.5) | |
|
|
Hydroxychloroquine | 82 (79.6) | |
|
|
Antiviral medication: Kaletra (combination lopinavir/rapinavir) | 54 (52.4) | |
|
|
Insulin administered on admission, n (%) | 63 (61.2) | |
|
|
|
Intravenous insulin | 10 (9.7) |
|
|
|
Subcutaneous insulin | 53 (51.5) |
|
|
Units of insulin per 24 h, mean (SD) | 29.6 (25.6) | |
| Outcomes | |||
|
|
Hypoglycemia, n (%) | 5 (4.9) | |
|
|
|
Insulin | 4 (3.8) |
|
|
|
Hydroxychloroquine | 2 (1.9) |
|
|
|
End-stage renal disease | 1 (0.9) |
|
|
Required ICUa, n (%) | 29 (28.2) | |
|
|
|
Need ventilation, n (%) | 12 (11.7) |
|
|
|
Need ECMOb, n (%) | 2 (1.9) |
|
|
|
Total deaths (all in ICU), n (%) | 5 (4.9) |
aICU: intensive care unit.
bECMO: extracorporeal membrane oxygenation.